Growing Incidence of Congestive Heart Failure Drives Global Dilated Cardiomyopathy Therapeutics Market

1. Transparency Market Research Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 Published Date 20-Mar-2015 90 Page Report Request Sample Buy Now Press Release Dilated Cardiomyopathy Therapeutics Market to Decline at -7.0% CAGR from 2014- 2020 owing to the Availability of Implantable Devices Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com

2. Dilated Cardiomyopathy Therapeutics Market REPORT DESCRIPTION A new report has been published by Transparency Market Research, titled “Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”. TMR, a market intelligence company based in the U.S., states that the global dilated cardiomyopathy (DCM) market was estimated at US$651.0 million in 2013 and is expected to reach US$328.6 million in 2020, declining at a -7.0% CAGR between 2014 and 2020. Browse Full Report with TOC: http://www.transparencymarketresearch.com/dilated-cardiomyopathy- market.html Dilated cardiomyopathy is an important cause of heart failure and is one of the leading indications for heart transplantation across the globe. It is characterized by the enlargement of ventricular chamber along with systolic dysfunction. Dilated cardiomyopathy can develop at any age but it is more common among people aged between 20 years and 60 years. According to American Society for Clinical Investigation about 25% - 50% of the total dilated cardiomyopathy cases are genetically caused, owing to mutation in genes encoding for cytoskeleton, contractile, or other proteins in myocardial cells. The global dilated cardiomyopathy therapeutics market is studied in this report from three perspectives: by drug class, by pipelined products and by geography. Dilated cardiomyopathy therapeutics market by drug class encompasses aldosterone antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and beta-blockers. A detailed market analysis and forecast for each of these segments have been provided in this study, in terms of market revenue (USD million) for the period 2012 to 2020. The report also provides the compounded annual growth rate (CAGR %) for each of these segments for the forecast period from 2014 to 2020, considering 2012 and 2013 as base years. Geographic regions analyzed for this market include North America, Europe, Asia Pacific and Rest of the World. The North American market comprises the United States and Canada. The European market includes countries such as the U.K., Germany, Italy, and Spain that 2 Transparency Market Research

3. Dilated Cardiomyopathy Therapeutics Market majorly contribute towards the growth of this region. Similarly, the Asia Pacific market primarily considers India, China, Japan, Singapore, and Australia, along with other smaller markets. The market overview section of the report demonstrates the major factors determining the market dynamics such as drivers, restraints and opportunities that influence the current as well as future status of this industry. The market overview section of the report also includes qualitative and quantitative analysis of the competitive landscape covering market share analysis by key players. Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293 The study also suggests a list of recommendations which would be useful for existing and future market players in decision making for business growth. Pipeline analysis (Phase I and Phase II) for dilated cardiomyopathy therapeutics market has also been covered in the report. The report concludes with the company profiles section, which illustrates key information about the major players in this market such as company overview, financial overview, product portfolio, business strategies and recent developments. Key players profiled in the report include Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, and Vericel Corporation. The global dilated cardiomyopathy therapeutics market is segmented into the following categories: Dilated cardiomyopathy therapeutics market, by drug class Aldosterone antagonists Angiotensin-converting enzyme (ACE) inhibitors Angiotensin II receptor blockers (ARBs) Beta-blockers Dilated cardiomyopathy therapeutics market, by pipeline drugs 3 Transparency Market Research

4. Dilated Cardiomyopathy Therapeutics Market ARRY-797 ixCELL-DCM MYDICAR OR-1 CAP-1002 Dilated cardiomyopathy therapeutics market, by geography North America Europe Asia Pacific Rest of the World (RoW) Browse Full Press Release @ http://www.transparencymarketresearch.com/pressrelease/dilated- cardiomyopathy-market.htm TABLE OF CONTENT Chapter 1 Introduction 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.3.1 Secondary Research 1.3.2 Primary Research 1.4 List of Abbreviations 1.5 Assumptions and Stipulations Chapter 2 Executive Summary 2.1 Market Snapshot: Global Dilated Cardiomyopathy Therapeutics Market (2013 & 2020) 4 Transparency Market Research

5. Dilated Cardiomyopathy Therapeutics Market 2.2 Comparative Analysis: Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2013 & 2020 (Value %) Chapter 3 Global Dilated Cardiomyopathy Therapeutics Market Overview 3.1 Market Definition and Overview 3.1.1 Classification of Cardiomyopathies 3.1.2 Market Drivers 3.1.2.1 Increasing number of heart failure cases worldwide will lead to rise in demand for effective medications, thereby driving market growth 3.1.3 Market Restraints 3.1.3.1 Side effects associated with DCM drugs could restrain market growth 3.1.3.2 Enhanced relief from use of devices without any side effects will restrain the dilated cardiomyopathy drugs market 3.1.4 Promising gene and stem cell therapies for DCM treatment may hamper the DCM drugs market growth 3.1.5 Market Opportunities 3.1.7 Increasing genericization of DCM drugs 3.2 Market Attractiveness Analysis: Global Dilated Cardiomyopathy Therapeutics Market, by Geography, 2013 3.3 Epidemiology (Prevalence, Cause, Mortality Rate) 3.4 Epidemiology Studies on Dilated Cardiomyopathy 3.5 Causes and Mortality 3.6 Event Impact Analysis 3.7 Competitive Landscape, by Key Players, 2013 (Value %) 3.7.1 Market share by key players, 2013 (Value %) Chapter 4 Global Dilated Cardiomyopathy Therapeutics Market, by Drug Class 4.1 Introduction 4.1.1 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Drug Class 2012 – 2020 (USD Million) 4.2 Aldosterone Antagonists 4.2.1 Global Aldosterone Antagonists Market Revenue, 2012 - 2020 (USD Million) 5 Transparency Market Research

6. Dilated Cardiomyopathy Therapeutics Market 4.3 Angiotensin-Converting Enzymes (ACE) Inhibitors 4.3.1 Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market Revenue, 2012 - 2020 (USD Million) 4.4 Angiotensin II Receptor Blocker (ARBs) 4.4.1 Global Angiotensin II Receptor Blockers (ARBs) Market Revenue, 2012 - 2020 (USD Million) 4.5 Beta-Blockers 4.5.1 Global Beta-Blockers Market Revenue, 2012 - 2020 (USD Million) Chapter 5 Pipeline Analysis of Global Dilated Cardiomyopathy Therapeutics Market 5.1 Pipeline Analysis 5.1.1 Pipeline Analysis : Dilated Cardiomyopathy Therapeutics Market Chapter 6 Global Dilated Cardiomyopathy Therapeutics Market, by Geography 6.1 Introduction 6.1.1 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million) 6.2 North America 6.2.1 North America Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million) 6.3 Europe 6.3.1 Europe Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million) 6.4 Asia Pacific 6.4.1 Asia Pacific Dilated Cardiomyopathy Therapeutics market Revenue, 2012 - 2020 (USD Million) 6.5 Rest of the World (RoW) 6.5.1 Rest of the World Dilated Cardiomyopathy Therapeutics Market Revenue, 2012 - 2020 (USD Million) Chapter 7 Recommendations 7.1 Dilated phase of hypertrophic cardiomyopathy 7.2 Genetic Intervention Chapter 8 Company Profiles 8.1 Array BioPharma, Inc. 6 Transparency Market Research

7. Dilated Cardiomyopathy Therapeutics Market 8.1.1 Company Overview 8.1.2 Financial Overview 8.1.3 Product Portfolio 8.1.4 Business Strategies 8.1.5 Recent Developments 8.2 AstraZeneca plc 8.2.1 Company Overview 8.2.2 Financial Overview 8.2.3 Product Portfolio 8.2.4 Business Strategies 8.2.5 Recent Developments 8.3 Celladon Corporation 8.3.1 Company Overview 8.3.2 Financial Overview 8.3.3 Product Portfolio 8.3.4 Business Strategies 8.3.5 Recent Developments 8.4 GlaxoSmithKline plc 8.4.1 Company Overview 8.4.2 Financial Overview 8.4.3 Product Portfolio 8.4.4 Business Strategies 8.4.5 Recent Developments 8.5 Janssen Pharmaceuticals, Inc. 8.5.1 Company Overview 8.5.2 Financial Overview 8.5.3 Product Portfolio 8.5.4 Business Strategies 8.5.5 Recent Developments 8.6 Merck & Co., Inc. 7 Transparency Market Research

8. Dilated Cardiomyopathy Therapeutics Market 8.6.1 Company Overview 8.6.2 Financial Overview 8.6.3 Product Portfolio 8.6.4 Business Strategies 8.6.5 Recent Developments 8.7 Novartis International AG 8.7.1 Company Overview 8.7.2 Financial Overview 8.7.3 Product Portfolio 8.7.4 Business Strategies 8.7.5 Recent Developments 8.8 Pfizer, Inc. 8.8.1 Company Overview 8.8.2 Financial Overview 8.8.3 Product Portfolio 8.8.4 Business Strategies 8.8.5 Recent Developments 8.9 Sanofi S.A. 8.9.1 Company Overview 8.9.2 Financial Overview 8.9.3 Product Portfolio 8.9.4 Business Strategies 8.9.5 Recent Developments 8.10 Teva Pharmaceutical Industries Ltd. 8.10.1 Company Overview 8.10.2 Financial Overview 8.10.3 Product Portfolio 8.10.4 Business Strategies 8.10.5 Recent Developments 8.11 Vericel Corporation 8 Transparency Market Research

9. Dilated Cardiomyopathy Therapeutics Market 8.11.1 Company Overview 8.11.2 Financial Overview 8.11.3 Product Portfolio 8.11.4 Business Strategies 8.11.5 Recent Developments About Us Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations. Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Browse Market Research Blog : https://marketsresearchindustry.wordpress.com/ 9 Transparency Market Research